Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR-mutant Lung Cancer.

Molecular cancer therapeutics - 1 Mar 2017

Nanjo Shigeki, Arai Sachiko, Wang Wei, Takeuchi Shinji, Yamada Tadaaki, Hata Akito, Katakami Nobuyuki, Okada Yasunori, Yano Seiji

Abstract excerpt

Leptomeningeal carcinomatosis occurs frequently in EGFR-mutant lung cancer, and develops acquired resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs). This study aimed to clarify the mechanism of EGFR-TKI resistance in leptomeningeal carcinomatosis and seek for a novel therapeutic strategy. We examined EGFR mutations, including the T790M gatekeeper mutation, in 32 re-biopsy specimens from 12 leptomeningeal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Gefitinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Dosage

Share to Meningeal Carcinomatosis

Share to Neoplasms, Second Primary

Share to Proto-Oncogene Proteins c-met

Share to Quinazolines

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 28138027
DOI: 10.1158/1535-7163.MCT-16-0522

Genes

EGFR
MET

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR-mutant Lung Cancer.PMID 28138027Read ↗

Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.Semantic proximity Read ↗

High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells.Semantic proximity Read ↗

Promising Effects of Afatinib on Leptomeningeal Carcinomatosis Derived from Erlotinib-resistant Lung Adenocarcinoma.Semantic proximity Read ↗

High-Dose Furmonertinib in Patients With EGFR-Mutated NSCLC and Leptomeningeal Metastases: A Prospective Real-World Study.Semantic proximity Read ↗

Leptomeningeal metastases in non-small-cell lung cancer.Semantic proximity Read ↗

Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer.Semantic proximity Read ↗

Cell-Cycle and DNA-Damage Response Pathway Is Involved in Leptomeningeal Metastasis of Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.Semantic proximity Read ↗

Successful Remedy With Osimertinib in a Patient of Thr790Met-positive Non-small Cell Lung Cancer With Leptomeningeal Carcinomatosis and Resistant to GefitinibSemantic proximity Read ↗

Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation.Semantic proximity Read ↗

Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure.Semantic proximity Read ↗

Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.